Cargando…
Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study
Administering double doses of infliximab or shortening its dosing interval for patients with Crohn disease who experience a loss of response to treatment is an accepted treatment method; however, the effectiveness and appropriate timing of treatment intensification remain unclear. We examined the tr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545267/ https://www.ncbi.nlm.nih.gov/pubmed/33578618 http://dx.doi.org/10.1097/MD.0000000000024731 |
_version_ | 1785114636301893632 |
---|---|
author | Komaki, Yuga Kanmura, Shuji Yutsudo, Kazuki Kuwazuru, Kosuke Komaki, Fukiko Tanaka, Akihito Nishimata, Nobuaki Sameshima, Yoichi Sasaki, Fumisato Ohi, Hidehisa Nakamura, Yuichi Tokushige, Koichi Sameshima, Yukinori Ido, Akio |
author_facet | Komaki, Yuga Kanmura, Shuji Yutsudo, Kazuki Kuwazuru, Kosuke Komaki, Fukiko Tanaka, Akihito Nishimata, Nobuaki Sameshima, Yoichi Sasaki, Fumisato Ohi, Hidehisa Nakamura, Yuichi Tokushige, Koichi Sameshima, Yukinori Ido, Akio |
author_sort | Komaki, Yuga |
collection | PubMed |
description | Administering double doses of infliximab or shortening its dosing interval for patients with Crohn disease who experience a loss of response to treatment is an accepted treatment method; however, the effectiveness and appropriate timing of treatment intensification remain unclear. We examined the treatment outcomes of patients with Crohn disease receiving infliximab therapy intensification. Among 430 patients with Crohn disease who were seen at our related facilities from July 2002 to July 2018, 46 patients (30 men and 16 women) who were followed up for diminished infliximab effects for >1 year after therapy intensification were included in this study. The relationship between patient background and continuation of therapy intensification was retrospectively examined through a logistic regression analysis. Among the 46 patients, 67.4% (31 cases) continued therapy intensification for 12 months. The treatment discontinuation rate after 12 months (7.1% vs 43.8%, P = .015) and the C-reactive protein levels at the start of therapy intensification (P = .0050) were significantly lower in the group in which treatment was strengthened due to remaining endoscopic findings (n = 14) than that due to clinical symptoms (n = 32). There was no significant difference in the rates of treatment discontinuation after 12 months of treatment strengthening between patients receiving double doses (n = 34) and those with shortened dosing intervals (n = 12). Infliximab treatment discontinuation seems to be less likely to occur in patients with Crohn disease who are receiving infliximab treatment intensification based on endoscopic findings of exacerbations than in patients whose treatment is based on clinical symptoms. |
format | Online Article Text |
id | pubmed-10545267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-105452672023-10-03 Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study Komaki, Yuga Kanmura, Shuji Yutsudo, Kazuki Kuwazuru, Kosuke Komaki, Fukiko Tanaka, Akihito Nishimata, Nobuaki Sameshima, Yoichi Sasaki, Fumisato Ohi, Hidehisa Nakamura, Yuichi Tokushige, Koichi Sameshima, Yukinori Ido, Akio Medicine (Baltimore) 4500 Administering double doses of infliximab or shortening its dosing interval for patients with Crohn disease who experience a loss of response to treatment is an accepted treatment method; however, the effectiveness and appropriate timing of treatment intensification remain unclear. We examined the treatment outcomes of patients with Crohn disease receiving infliximab therapy intensification. Among 430 patients with Crohn disease who were seen at our related facilities from July 2002 to July 2018, 46 patients (30 men and 16 women) who were followed up for diminished infliximab effects for >1 year after therapy intensification were included in this study. The relationship between patient background and continuation of therapy intensification was retrospectively examined through a logistic regression analysis. Among the 46 patients, 67.4% (31 cases) continued therapy intensification for 12 months. The treatment discontinuation rate after 12 months (7.1% vs 43.8%, P = .015) and the C-reactive protein levels at the start of therapy intensification (P = .0050) were significantly lower in the group in which treatment was strengthened due to remaining endoscopic findings (n = 14) than that due to clinical symptoms (n = 32). There was no significant difference in the rates of treatment discontinuation after 12 months of treatment strengthening between patients receiving double doses (n = 34) and those with shortened dosing intervals (n = 12). Infliximab treatment discontinuation seems to be less likely to occur in patients with Crohn disease who are receiving infliximab treatment intensification based on endoscopic findings of exacerbations than in patients whose treatment is based on clinical symptoms. Lippincott Williams & Wilkins 2021-02-12 /pmc/articles/PMC10545267/ /pubmed/33578618 http://dx.doi.org/10.1097/MD.0000000000024731 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 4500 Komaki, Yuga Kanmura, Shuji Yutsudo, Kazuki Kuwazuru, Kosuke Komaki, Fukiko Tanaka, Akihito Nishimata, Nobuaki Sameshima, Yoichi Sasaki, Fumisato Ohi, Hidehisa Nakamura, Yuichi Tokushige, Koichi Sameshima, Yukinori Ido, Akio Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title | Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title_full | Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title_fullStr | Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title_full_unstemmed | Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title_short | Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: A retrospective cohort study |
title_sort | infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with crohn disease: a retrospective cohort study |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545267/ https://www.ncbi.nlm.nih.gov/pubmed/33578618 http://dx.doi.org/10.1097/MD.0000000000024731 |
work_keys_str_mv | AT komakiyuga infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT kanmurashuji infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT yutsudokazuki infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT kuwazurukosuke infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT komakifukiko infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT tanakaakihito infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT nishimatanobuaki infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT sameshimayoichi infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT sasakifumisato infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT ohihidehisa infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT nakamurayuichi infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT tokushigekoichi infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT sameshimayukinori infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy AT idoakio infliximabtherapyintensificationbasedonendoscopicactivityisrelatedtosuppresstreatmentdiscontinuationinpatientswithcrohndiseasearetrospectivecohortstudy |